Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06667752

Randomized Double-Blind Trial on Safety and Efficacy of Nanordica Advanced Antibacterial Wound Dressing for Diabetic Foot Ulcer

Led by Nanordica Medical OU · Updated on 2025-08-27

170

Participants Needed

11

Research Sites

88 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This clinical trial evaluates the safety and efficacy of the Nanordica Advanced Antibacterial Wound Dressing (AAWD) in patients suffering from diabetic foot ulcers. At least 170 participants will be randomly allocated to be treated either with AAWD or Aquacel Ag+ Extra wound dressing for a 4-week active phase (intervention) followed by an 8-week standard of care period.

CONDITIONS

Official Title

Randomized Double-Blind Trial on Safety and Efficacy of Nanordica Advanced Antibacterial Wound Dressing for Diabetic Foot Ulcer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Provided voluntary, written informed consent before any study activities
  • Male or female aged 18 years or older
  • Diabetic foot ulcer(s) present for more than 4 weeks with a maximum size of 4 cm diameter
  • Wound infection graded 1 (absent) or 2 according to IWGDF/IDSA
  • Willing and able to attend scheduled visits, laboratory tests, and study procedures
  • Ankle-brachial index (ABI) between 0.9 and 1.4, or ABI between 0.6 and 0.9 with ankle pressure at least 70 mmHg
Not Eligible

You will not qualify if you...

  • Received systemic or topical antibiotic therapy within 7 days before enrollment
  • Any wound with known osteomyelitis or positive probe-to-bone test
  • Previously randomized in this clinical trial
  • Surgical procedures on the same leg as the index ulcer(s) within past 4 weeks or planned during the study
  • Use of other advanced therapies involving the index ulcer(s) within past 4 weeks
  • Cardiac disorders classified as NYHA grade IV
  • Hepatic disorders classified as Child-Pugh grade C
  • Stage 4 cancer
  • Women of childbearing potential who are pregnant, breastfeeding, or not using adequate contraception

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 11 locations

1

East Tallinn Central Hospital

Tallinn, Harju, Estonia

Actively Recruiting

2

North Estonia Medical Centre Foundation

Tallinn, Harju, Estonia

Actively Recruiting

3

Tartu University Hospital

Tartu, Tartu, Estonia

Actively Recruiting

4

Centro de Salud de Arcos de la Frontera

Arcos de la Frontera, Cádiz, Spain

Actively Recruiting

5

Hospital Puerta del Mar

Cadiz, Cádiz, Spain

Actively Recruiting

6

Centro de Salud San Benito

Jerez de la Frontera, Cádiz, Spain

Actively Recruiting

7

Hospital de León

León, León, Spain

Actively Recruiting

8

Clínica Universitaria de Podología de la Universidad Complutense de Madrid

Madrid, Madrid, Spain

Actively Recruiting

9

Hospital Ramón y Cajal

Madrid, Spain

Actively Recruiting

10

Hospital Universitario Fundación Alcorcón

Madrid, Spain

Actively Recruiting

11

Hospital Universitario de Donostia

San Sebastián, Spain

Actively Recruiting

Loading map...

Research Team

G

Grigory Vasiliev

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here